by bizlift | Jan 1, 2019
PUBLIC | NASDAQ:EDIT Building the leading genome editing company dedicated to treating patients with genetically defined diseases. https://editasmedicine.com Press Releases Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and...
